NCT01250366已完成1 期
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Bristol-Myers Squibb0 个研究点目标入组 70 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 主要终点
- Safety will be evaluated in an integrated way on the basis of the Adverse Event profiles, changes in laboratory values (serum chemistry, hematology and urinalysis), ECG data, and vital signs, viral resistance testing and results of Physical Exams.
研究概览
简要总结
The purpose of this study is to determine the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects.
详细描述
This is a multi-center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose, 7-day treatment study in chronically-infected genotype 1 HCV, treatment-naïve subjects.
Primary Objectives include:
Safety
• to evaluate the safety of ascending oral doses of INX-08189 given once a day for seven (7) days in chronically-infected genotype 1 HCV, treatment-naïve subjects
Pharmacokinetic
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At the screening visit (Visit 1), subjects will meet the following criteria:
- •Males & females, 18 - 65 years of age inclusive(BMI of at least 18kg/m2 not exceeding 36kg/m2);
- •Diagnosis of chronic HCV by 1 previous PCR result prior to screening, with a positive HCV viral load of at least 100,000IU/ml at screening measured by quantitative PCR;
- •HCV genotype 1 per central lab testing report;
- •HCV treatment-naïve (defined as no prior treatment with interferon, pegylated interferon, ribavirin, or any HCV direct acting anti-viral drugs);
- •Liver biopsy consistent with chronic HCV infection but non-cirrhotic as judged by a pathologist (Knodell < 3, Metavir <2, Ishak <4, or Batts & Ludwig <2) within the last 2 years & before Visit 2 (biopsy can be done within screening period);
- •Negative urine drug screen for drugs of abuse at screening and Study Day -1 (methadone use allowed);
- •Females will have a negative serum βHCG pregnancy test at screening & negative urine dipstick pregnancy test upon entry to clinical unit on Study Day -1;
- •Agreement by both females of childbearing potential & males(who have not been surgically sterilized) to practice an acceptable method of birth control. Surgical sterilization of either female or male partner must have occurred at least 6 month prior to first dose & females must be post-menopausal for 2 years to be considered of non-child-bearing potential. Acceptable contraceptive methods include 1 of the following: Oral & implantable hormonal contraceptives by female at least 3 months prior to the 1st dose of Study Drug, IUD in place at least 6 months prior to first dose, barrier methods either diaphragm or condom with spermicide. (Abstinence is not an acceptable method of birth control, subjects who indicate sexual inactivity must agree to utilize birth control in the event of sexual activity);
- •Willing & able to complete all study visits and procedures, & able to communicate with the investigator & other personnel;
- •Signed informed consent form (ICF) executed prior to protocol screening assessments
排除标准
- •At the screening visit subjects will not meet any of the following criteria:
- •Advanced liver disease, cirrhosis, or with signs of decompensated liver disease such as variceal bleeding, ascites, hepatic encephalopathy, active jaundice (total bilirubin > 2, or other evidence of decompensated liver disease;
- •Co-infection with HBV or HIV (positive test for HBsAg or anti-HIV Ab);
- •Acute cardiac ischemia, unstable heart disease or clinically symptomatic cardiac abnormalities apparent on ECG & PE, or a QTcB interval at Visit 1 of ≥ to 450ms by Bazette's correction, or personal or family history of Torsades de pointes;
- •Use of the following medications concurrently or within the 30 days prior to Screening associated with QT prolongation: macrolides, antiarrhythmic agents, azoles, fluoroquinolones, & tricyclic anti-depressants (methadone use allowed);
- •Use of immunosuppressive or immune-modulating agents (including corticosteroids & immunosuppressive agents) or presence of an immunologically-mediated autoimmune disease (other than asthma) or history of organ transplantation (inhaled steroids for asthma & topical steroid for minor skin conditions allowed);
- •Use of strong CYP3A4-inhibiting protease inhibitors (specifically atazanavir, indinavir, nelfinavir, saquinavir, & ritonavir), strong CYP3A4 inhibitors (specifically clarithromycin, itraconazole, ketoconazole, nefazodone, telithromycin), or strong CYP3A4 inducers (specifically rifampin, efavirenz, etravirine, phenobarbital, phenytoin, & carbamazepine);
- •Absolute NEUT count of <1800 cells/mm3 (or < 1500 cells/mm3 for African Americans), or platelet count <130,000 cells/mm3, or hemoglobin <11g/dl for women and <13g/dl for men;
- •A history of abnormal thyroid function not adequately controlled (defined as TSH levels < 0.8 x LLN or > 1.2 x the ULN);
- •Serum creatinine concentration > 1.5 times the upper limit of normal, or albumin < 3g/dl;
- •Presence or history of severe, or uncontrolled, or hospitalization-requiring psychiatric disease including severe depression, suicide attempts or any severity of psychosis;
- •Any malignancy within the last 5 years other than treated cervical carcinoma in situ or treated basal cell carcinoma with no more than 20% risk of recurrence within 2 years;
- •Alcohol abuse (investigator assessment) within the past 2 years or an alcohol use pattern that will interfere with the study conduct;
- •Drug abuse (investigator assessment)within the last 6 months with exception of methadone;
- •Current lactation or breastfeeding;
- •Major surgery within 30 days prior Visit 1;
- •Participation in another clinical trial of an investigational drug or device within 6 months prior to visit 1;
- •Donation of blood or plasma within 30 days prior to Visit 1
研究组 & 干预措施
Arm 2: INX-08189 (25 mg) or Placebo
Experimental
干预措施: INX-08189 (Drug)
Arm 1: INX-08189 (9 mg) or Placebo
Experimental
干预措施: INX-08189 (Drug)
Arm 1: INX-08189 (9 mg) or Placebo
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
Arm 2: INX-08189 (25 mg) or Placebo
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
Arm 3: INX-08189 (50 mg + 9 mg) or Placebo
Experimental
干预措施: INX-08189 (Drug)
Arm 3: INX-08189 (50 mg + 9 mg) or Placebo
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
Arm 4: INX-08189 (50 mg) or Placebo
Experimental
干预措施: INX-08189 (Drug)
Arm 4: INX-08189 (50 mg) or Placebo
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin
Experimental
干预措施: INX-08189 (Drug)
Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin
Experimental
干预措施: Ribavirin (Drug)
Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin
Experimental
干预措施: INX-08189 (Drug)
Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin
Experimental
干预措施: Ribavirin (Drug)
Arm 7: INX-08189 (100 mg) or Placebo
Experimental
干预措施: INX-08189 (Drug)
Arm 7: INX-08189 (100 mg) or Placebo
Experimental
干预措施: Placebo matching with INX-08189 (Drug)
结局指标
主要结局
Safety will be evaluated in an integrated way on the basis of the Adverse Event profiles, changes in laboratory values (serum chemistry, hematology and urinalysis), ECG data, and vital signs, viral resistance testing and results of Physical Exams.
时间窗: periodically over 14 days
PK parameters following administration of INX-08189 will be determined using concentration data obtained via the assay of INX-08189 and INX-08032 in plasma, and the analysis of INX-08032 in urine
时间窗: periodically over 14 days
The primary efficacy outcome is the maximum change from baseline in HCV RNA following 7 days of dosing.
时间窗: 7 days
次要结局
- Secondary efficacy outcome measures include the change in HCV RNA over time during the seven days of dosing and during the follow-up period thereafter. Additionally, viral load changes will be compared across the two genotypes 1a and 1b.(14 days)
研究者
相似试验
已完成
1 期
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentHealthy ParticipantsNCT05546151Bristol-Myers Squibb24
已完成
1 期
Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy SubjectsAtherosclerosisNCT00836602Bristol-Myers Squibb25
终止
1 期
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With PsoriasisPsoriasisNCT03145948AbbVie12
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in HealthyHealthy SubjectsOsteoarthritisNCT00380900Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive DisorderMajor Depressive DisorderNCT01670279Otsuka Pharmaceutical Development & Commercialization, Inc.18